Last reviewed · How we verify
DCVAC and immune enhancers add on to SOC
DCVAC and immune enhancers add on to SOC is a Biologic drug developed by SOTIO a.s.. It is currently in Phase 1 development.
At a glance
| Generic name | DCVAC and immune enhancers add on to SOC |
|---|---|
| Sponsor | SOTIO a.s. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DCVAC and immune enhancers add on to SOC CI brief — competitive landscape report
- DCVAC and immune enhancers add on to SOC updates RSS · CI watch RSS
- SOTIO a.s. portfolio CI
Frequently asked questions about DCVAC and immune enhancers add on to SOC
What is DCVAC and immune enhancers add on to SOC?
DCVAC and immune enhancers add on to SOC is a Biologic drug developed by SOTIO a.s..
Who makes DCVAC and immune enhancers add on to SOC?
DCVAC and immune enhancers add on to SOC is developed by SOTIO a.s. (see full SOTIO a.s. pipeline at /company/sotio-a-s).
What development phase is DCVAC and immune enhancers add on to SOC in?
DCVAC and immune enhancers add on to SOC is in Phase 1.